Patents Examined by Julie Wu
  • Patent number: 10912831
    Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: February 9, 2021
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • Patent number: 10913801
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 (PD-1), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 9, 2021
    Inventors: Hemanta Baruah, Cheng Chen, Xiaolin Liu, Andy Tsun, De-Chao Michael Yu
  • Patent number: 10793640
    Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: October 6, 2020
    Assignee: GENMAB A/S
    Inventors: Bart De Goeij, Edward N. Van Den Brink, Simone De Haij, Thilo Riedl, Rene Hoet, Ole Baadsgaard, David Satijn, Jan Van De Winkel, Paul Parren
  • Patent number: 10792316
    Abstract: The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 6, 2020
    Assignee: CHR. HANSEN A/S
    Inventors: Birgitte Yde, Jakob Blenker Svendsen
  • Patent number: 10787684
    Abstract: Methods of simultaneously excising large nucleic acid sequences from a target nucleic acid and inserting large foreign nucleic sequences into the target nucleic acid sequence using DNA binding protein nucleases are described.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: September 29, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Susan M. Byrne, George M. Church
  • Patent number: 10786535
    Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: September 29, 2020
    Inventors: Siddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
  • Patent number: 10787514
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: September 29, 2020
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Patent number: 10766963
    Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGF?RII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: September 8, 2020
    Inventors: Nagaraj Govindappa, Maria Melina Soares, Kedernath Sastry
  • Patent number: 10759844
    Abstract: The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, VL and the heavy chain region, VH of the Fab molecule are linked by one or more disulfide bonds, and use of the same in treatment or prophylaxis.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: September 1, 2020
    Inventor: David Paul Humphreys
  • Patent number: 10745473
    Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: August 18, 2020
    Assignee: NOVARTIS AG
    Inventors: Matthew John Edwards, Jean-Michel Rene Rondeau, Danforth Miller, Daniel Huang, Hans-Peter Knopf, Gino Anselmus Van Heeke, Rene Hemmig, Kapil Gupta, Nicole Haubst, Barbara Andlauer
  • Patent number: 10745477
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 18, 2020
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Patent number: 10744204
    Abstract: This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: August 18, 2020
    Assignee: MedImmune, LLC
    Inventors: Changshou Gao, Godfrey Rainey, Cuihua Gao
  • Patent number: 10729810
    Abstract: The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: August 4, 2020
    Inventors: Stephen Douglas Barrett, Joseph Michael Colombo, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Gregory William Endres, Fred Lawrence Ciske, Thomas Allen Owen, James Paul O'Malley
  • Patent number: 10729740
    Abstract: The invention relates to conjugates that bind to Her2/neu, methods of using conjugates that bind to Her2/neu and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express Her2/neu.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: August 4, 2020
    Assignee: Esperance Pharmaceuticals, Inc.
    Inventors: Hector Alila, Carola Leuschner
  • Patent number: 10730945
    Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: August 4, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Z. Chen
  • Patent number: 10716837
    Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: July 21, 2020
    Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
  • Patent number: 10716864
    Abstract: An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: July 21, 2020
    Inventors: Ofer Mandelboim, Stipan Jonjic, Orit Berhani, Ariella Glasner
  • Patent number: 10717990
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 21, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Patent number: 10690681
    Abstract: The present invention provides an accurate and reliable method to detect acute cardiovascular syndromes or disorders and to detect acute cardiovascular syndromes or disorders at earlier time points such that more aggressive interventions can be used in high risk subjects
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: June 23, 2020
    Assignee: Washington University
    Inventors: Walter A. Boyle, Richard Bach
  • Patent number: 10683348
    Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee, Patrick Koenig